-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Viridian Therapeutics, Inc.\DE quarterly Earnings Per Share, Diluted history and growth rate from 2020 to 2024.
- Viridian Therapeutics, Inc.\DE Earnings Per Share, Diluted for the quarter ending March 31, 2024 was -0.79 USD/shares, a 50.9% increase year-over-year.
- Viridian Therapeutics, Inc.\DE Earnings Per Share, Diluted for the twelve months ending March 31, 2024 was -4.49 USD/shares, a 4.06% increase year-over-year.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly Data (USD/shares)